25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Assembly Biosciences Inc
Buy, Hold or Sell?

Let's analyze Assembly Biosciences Inc together

I guess you are interested in Assembly Biosciences Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Assembly Biosciences Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Assembly Biosciences Inc

I send you an email if I find something interesting about Assembly Biosciences Inc.

1. Quick Overview

1.1. Quick analysis of Assembly Biosciences Inc (30 sec.)










1.2. What can you expect buying and holding a share of Assembly Biosciences Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$4.09
Expected worth in 1 year
$1.62
How sure are you?
20.0%

+ What do you gain per year?

Total Gains per Share
$-2.47
Return On Investment
-17.1%

For what price can you sell your share?

Current Price per Share
$14.42
Expected price per share
$12.30 - $18.98
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Assembly Biosciences Inc (5 min.)




Live pricePrice per Share (EOD)
$14.42
Intrinsic Value Per Share
$-115.64 - $-51.65
Total Value Per Share
$-111.54 - $-47.56

2.2. Growth of Assembly Biosciences Inc (5 min.)




Is Assembly Biosciences Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$26m$62.4m-$28.8m-85.8%

How much money is Assembly Biosciences Inc making?

Current yearPrevious yearGrowGrow %
Making money-$10.2m-$17.8m$7.6m74.7%
Net Profit Margin-145.3%0.0%--

How much money comes from the company's main activities?

2.3. Financial Health of Assembly Biosciences Inc (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#507 / 933

Most Revenue
#327 / 933

Most Profit
#526 / 933

Most Efficient
#480 / 933
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Assembly Biosciences Inc?

Welcome investor! Assembly Biosciences Inc's management wants to use your money to grow the business. In return you get a share of Assembly Biosciences Inc.

First you should know what it really means to hold a share of Assembly Biosciences Inc. And how you can make/lose money.

Speculation

The Price per Share of Assembly Biosciences Inc is $14.42. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Assembly Biosciences Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Assembly Biosciences Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $4.09. Based on the TTM, the Book Value Change Per Share is $-0.62 per quarter. Based on the YOY, the Book Value Change Per Share is $1.11 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Assembly Biosciences Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-1.51-10.5%-1.60-11.1%-2.86-19.8%-1.24-8.6%-0.97-6.7%
Usd Book Value Change Per Share-1.37-9.5%-0.62-4.3%1.117.7%-0.10-0.7%-0.04-0.3%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-1.37-9.5%-0.62-4.3%1.117.7%-0.10-0.7%-0.04-0.3%
Usd Price Per Share15.14-10.75-1.04-7.42-13.83-
Price to Earnings Ratio-2.50--1.73--0.09--2.15--5.98-
Price-to-Total Gains Ratio-11.09-3.10--0.30--80.93--51.84-
Price to Book Ratio3.70-2.23-0.11-1.28-2.61-
Price-to-Total Gains Ratio-11.09-3.10--0.30--80.93--51.84-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share14.42
Number of shares69
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.62-0.10
Usd Total Gains Per Share-0.62-0.10
Gains per Quarter (69 shares)-42.64-6.72
Gains per Year (69 shares)-170.55-26.89
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-171-1810-27-37
20-341-3520-54-64
30-512-5230-81-91
40-682-6940-108-118
50-853-8650-134-145
60-1023-10360-161-172
70-1194-12070-188-199
80-1364-13780-215-226
90-1535-15490-242-253
100-1705-17200-269-280

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%1.019.00.05.0%1.039.00.02.5%1.062.01.01.6%
Book Value Change Per Share1.03.00.025.0%2.010.00.016.7%5.015.00.025.0%8.032.00.020.0%12.048.04.018.8%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.064.00.0%
Total Gains per Share1.03.00.025.0%2.010.00.016.7%5.015.00.025.0%8.032.00.020.0%12.048.04.018.8%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Assembly Biosciences Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---1.365-0.618-55%1.112-223%-0.097-93%-0.040-97%
Book Value Per Share--4.0915.285-23%9.819-58%6.212-34%6.176-34%
Current Ratio--2.3592.882-18%7.042-67%9.055-74%11.887-80%
Debt To Asset Ratio--0.7410.717+3%0.177+318%0.258+187%0.257+188%
Debt To Equity Ratio--2.8562.551+12%0.216+1224%0.646+342%0.529+440%
Dividend Per Share----0%-0%-0%-0%
Enterprise Value--116929230.60095508994.957+22%60937763.317+92%317378135.833-63%393390000.070-70%
Eps---1.512-1.605+6%-2.858+89%-1.236-18%-0.972-36%
Ev To Ebitda Ratio---2.676-2.104-21%-0.804-70%-2.973+11%-5.488+105%
Ev To Sales Ratio--4.2713.448+24%infnan%infnan%infnan%
Free Cash Flow Per Share---2.3980.898-367%-2.771+16%-0.671-72%-0.556-77%
Free Cash Flow To Equity Per Share---2.3981.750-237%-2.572+7%-0.191-92%118.403-102%
Gross Profit Margin--1.0001.0040%1.0000%1.0010%1.0000%
Intrinsic Value_10Y_max---51.655--------
Intrinsic Value_10Y_min---115.635--------
Intrinsic Value_1Y_max---2.657--------
Intrinsic Value_1Y_min---4.562--------
Intrinsic Value_3Y_max---9.902--------
Intrinsic Value_3Y_min---19.873--------
Intrinsic Value_5Y_max---19.463--------
Intrinsic Value_5Y_min---41.825--------
Market Cap91657701.800-5%96234230.60068298494.957+41%6635013.317+1350%206238435.833-53%305803059.495-69%
Net Profit Margin---1.404-1.453+3%--100%-2.948+110%-3.360+139%
Operating Margin---1.601-1.659+4%--100%-3.033+90%-3.500+119%
Operating Ratio--2.6012.659-2%-+100%5.614-54%6.694-61%
Pb Ratio3.525-5%3.7012.234+66%0.111+3236%1.277+190%2.612+42%
Pe Ratio-2.384+5%-2.503-1.726-31%-0.092-96%-2.146-14%-5.985+139%
Price Per Share14.420-5%15.14010.745+41%1.044+1350%7.417+104%13.828+9%
Price To Free Cash Flow Ratio-1.503+5%-1.578-0.996-37%-0.099-94%-1.298-18%-4.807+205%
Price To Total Gains Ratio-10.561+5%-11.0883.105-457%-0.304-97%-80.925+630%-51.836+367%
Quick Ratio--3.8785.050-23%9.704-60%14.391-73%17.279-78%
Return On Assets---0.096-0.087-9%-0.242+152%-0.134+40%-0.112+17%
Return On Equity---0.370-0.309-16%-0.294-21%-0.200-46%-0.166-55%
Total Gains Per Share---1.365-0.618-55%1.112-223%-0.097-93%-0.040-97%
Usd Book Value--26003000.00033595750.000-23%62415000.000-58%146652850.000-82%132721701.400-80%
Usd Book Value Change Per Share---1.365-0.618-55%1.112-223%-0.097-93%-0.040-97%
Usd Book Value Per Share--4.0915.285-23%9.819-58%6.212-34%6.176-34%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Enterprise Value--116929230.60095508994.957+22%60937763.317+92%317378135.833-63%393390000.070-70%
Usd Eps---1.512-1.605+6%-2.858+89%-1.236-18%-0.972-36%
Usd Free Cash Flow---15244000.0005709500.000-367%-17611000.000+16%-14756473.500-3%-12050397.225-21%
Usd Free Cash Flow Per Share---2.3980.898-367%-2.771+16%-0.671-72%-0.556-77%
Usd Free Cash Flow To Equity Per Share---2.3981.750-237%-2.572+7%-0.191-92%118.403-102%
Usd Market Cap91657701.800-5%96234230.60068298494.957+41%6635013.317+1350%206238435.833-53%305803059.495-69%
Usd Price Per Share14.420-5%15.14010.745+41%1.044+1350%7.417+104%13.828+9%
Usd Profit---9613000.000-10201000.000+6%-17821500.000+85%-20071950.000+109%-17112332.350+78%
Usd Revenue--6845000.0007081500.000-3%-+100%5922550.000+16%3836743.750+78%
Usd Total Gains Per Share---1.365-0.618-55%1.112-223%-0.097-93%-0.040-97%
 EOD+3 -5MRQTTM+14 -24YOY+17 -195Y+11 -2610Y+9 -28

3.3 Fundamental Score

Let's check the fundamental score of Assembly Biosciences Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-2.384
Price to Book Ratio (EOD)Between0-13.525
Net Profit Margin (MRQ)Greater than0-1.404
Operating Margin (MRQ)Greater than0-1.601
Quick Ratio (MRQ)Greater than13.878
Current Ratio (MRQ)Greater than12.359
Debt to Asset Ratio (MRQ)Less than10.741
Debt to Equity Ratio (MRQ)Less than12.856
Return on Equity (MRQ)Greater than0.15-0.370
Return on Assets (MRQ)Greater than0.05-0.096
Total3/10 (30.0%)

3.4 Technical Score

Let's check the technical score of Assembly Biosciences Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5040.076
Ma 20Greater thanMa 5015.564
Ma 50Greater thanMa 10015.889
Ma 100Greater thanMa 20016.250
OpenGreater thanClose14.380
Total1/5 (20.0%)

4. In-depth Analysis

4.1 About Assembly Biosciences Inc

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial. The company also develops ABI-4334, a next-generation capsid assembly modulator, which is in Phase 1b clinical trial for the treatment of hepatitis B virus (HBV). In addition, it develops an oral non-nucleoside polymerase inhibitor targeting transplant-related herpesviruses; and a small molecule interferon-a receptor agonist targeting HBV and HDV. The company has collaboration agreements with Gilead Sciences, Inc. and BeiGene, Ltd. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

Fundamental data was last updated by Penke on 2025-01-16 13:10:04.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is unable to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Assembly Biosciences Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Assembly Biosciences Inc to the Biotechnology industry mean.
  • A Net Profit Margin of -140.4% means that $-1.40 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Assembly Biosciences Inc:

  • The MRQ is -140.4%. The company is making a huge loss. -2
  • The TTM is -145.3%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-140.4%TTM-145.3%+4.8%
TTM-145.3%YOY--145.3%
TTM-145.3%5Y-294.8%+149.5%
5Y-294.8%10Y-336.0%+41.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-140.4%-104.6%-35.8%
TTM-145.3%-216.4%+71.1%
YOY--208.6%+208.6%
5Y-294.8%-353.9%+59.1%
10Y-336.0%-488.0%+152.0%
4.3.1.2. Return on Assets

Shows how efficient Assembly Biosciences Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Assembly Biosciences Inc to the Biotechnology industry mean.
  • -9.6% Return on Assets means that Assembly Biosciences Inc generated $-0.10 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Assembly Biosciences Inc:

  • The MRQ is -9.6%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -8.7%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-9.6%TTM-8.7%-0.9%
TTM-8.7%YOY-24.2%+15.5%
TTM-8.7%5Y-13.4%+4.7%
5Y-13.4%10Y-11.2%-2.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-9.6%-12.7%+3.1%
TTM-8.7%-13.0%+4.3%
YOY-24.2%-12.3%-11.9%
5Y-13.4%-13.7%+0.3%
10Y-11.2%-15.7%+4.5%
4.3.1.3. Return on Equity

Shows how efficient Assembly Biosciences Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Assembly Biosciences Inc to the Biotechnology industry mean.
  • -37.0% Return on Equity means Assembly Biosciences Inc generated $-0.37 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Assembly Biosciences Inc:

  • The MRQ is -37.0%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -30.9%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-37.0%TTM-30.9%-6.1%
TTM-30.9%YOY-29.4%-1.5%
TTM-30.9%5Y-20.0%-10.9%
5Y-20.0%10Y-16.6%-3.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-37.0%-16.8%-20.2%
TTM-30.9%-17.8%-13.1%
YOY-29.4%-16.4%-13.0%
5Y-20.0%-20.6%+0.6%
10Y-16.6%-21.2%+4.6%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Assembly Biosciences Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Assembly Biosciences Inc is operating .

  • Measures how much profit Assembly Biosciences Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Assembly Biosciences Inc to the Biotechnology industry mean.
  • An Operating Margin of -160.1% means the company generated $-1.60  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Assembly Biosciences Inc:

  • The MRQ is -160.1%. The company is operating very inefficient. -2
  • The TTM is -165.9%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-160.1%TTM-165.9%+5.9%
TTM-165.9%YOY--165.9%
TTM-165.9%5Y-303.3%+137.4%
5Y-303.3%10Y-350.0%+46.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-160.1%-193.6%+33.5%
TTM-165.9%-321.1%+155.2%
YOY--227.9%+227.9%
5Y-303.3%-373.0%+69.7%
10Y-350.0%-506.1%+156.1%
4.3.2.2. Operating Ratio

Measures how efficient Assembly Biosciences Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 2.60 means that the operating costs are $2.60 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Assembly Biosciences Inc:

  • The MRQ is 2.601. The company is inefficient in keeping operating costs low. -1
  • The TTM is 2.659. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ2.601TTM2.659-0.059
TTM2.659YOY-+2.659
TTM2.6595Y5.614-2.955
5Y5.61410Y6.694-1.080
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.6012.171+0.430
TTM2.6593.250-0.591
YOY-3.231-3.231
5Y5.6144.838+0.776
10Y6.6946.440+0.254
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Assembly Biosciences Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Assembly Biosciences Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 2.36 means the company has $2.36 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Assembly Biosciences Inc:

  • The MRQ is 2.359. The company is able to pay all its short-term debts. +1
  • The TTM is 2.882. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ2.359TTM2.882-0.523
TTM2.882YOY7.042-4.160
TTM2.8825Y9.055-6.173
5Y9.05510Y11.887-2.832
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.3593.610-1.251
TTM2.8823.850-0.968
YOY7.0424.605+2.437
5Y9.0555.895+3.160
10Y11.8876.178+5.709
4.4.3.2. Quick Ratio

Measures if Assembly Biosciences Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Assembly Biosciences Inc to the Biotechnology industry mean.
  • A Quick Ratio of 3.88 means the company can pay off $3.88 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Assembly Biosciences Inc:

  • The MRQ is 3.878. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 5.050. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ3.878TTM5.050-1.172
TTM5.050YOY9.704-4.655
TTM5.0505Y14.391-9.341
5Y14.39110Y17.279-2.889
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.8783.034+0.844
TTM5.0503.355+1.695
YOY9.7044.297+5.407
5Y14.3915.890+8.501
10Y17.2796.434+10.845
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Assembly Biosciences Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Assembly Biosciences Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Assembly Biosciences Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.74 means that Assembly Biosciences Inc assets are financed with 74.1% credit (debt) and the remaining percentage (100% - 74.1%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Assembly Biosciences Inc:

  • The MRQ is 0.741. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.717. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.741TTM0.717+0.023
TTM0.717YOY0.177+0.540
TTM0.7175Y0.258+0.459
5Y0.25810Y0.257+0.001
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7410.341+0.400
TTM0.7170.343+0.374
YOY0.1770.310-0.133
5Y0.2580.366-0.108
10Y0.2570.385-0.128
4.5.4.2. Debt to Equity Ratio

Measures if Assembly Biosciences Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Assembly Biosciences Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 285.6% means that company has $2.86 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Assembly Biosciences Inc:

  • The MRQ is 2.856. The company is unable to pay all its debts with equity. -1
  • The TTM is 2.551. The company is unable to pay all its debts with equity. -1
Trends
Current periodCompared to+/- 
MRQ2.856TTM2.551+0.305
TTM2.551YOY0.216+2.335
TTM2.5515Y0.646+1.905
5Y0.64610Y0.529+0.117
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.8560.393+2.463
TTM2.5510.429+2.122
YOY0.2160.382-0.166
5Y0.6460.439+0.207
10Y0.5290.489+0.040
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Assembly Biosciences Inc generates.

  • Above 15 is considered overpriced but always compare Assembly Biosciences Inc to the Biotechnology industry mean.
  • A PE ratio of -2.50 means the investor is paying $-2.50 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Assembly Biosciences Inc:

  • The EOD is -2.384. Based on the earnings, the company is expensive. -2
  • The MRQ is -2.503. Based on the earnings, the company is expensive. -2
  • The TTM is -1.726. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.384MRQ-2.503+0.119
MRQ-2.503TTM-1.726-0.776
TTM-1.726YOY-0.092-1.634
TTM-1.7265Y-2.146+0.420
5Y-2.14610Y-5.985+3.838
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.384-2.247-0.137
MRQ-2.503-2.693+0.190
TTM-1.726-3.214+1.488
YOY-0.092-3.335+3.243
5Y-2.146-6.368+4.222
10Y-5.985-6.692+0.707
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Assembly Biosciences Inc:

  • The EOD is -1.503. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -1.578. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -0.996. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.503MRQ-1.578+0.075
MRQ-1.578TTM-0.996-0.582
TTM-0.996YOY-0.099-0.897
TTM-0.9965Y-1.298+0.302
5Y-1.29810Y-4.807+3.508
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.503-2.993+1.490
MRQ-1.578-3.671+2.093
TTM-0.996-4.037+3.041
YOY-0.099-4.482+4.383
5Y-1.298-8.190+6.892
10Y-4.807-9.383+4.576
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Assembly Biosciences Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 3.70 means the investor is paying $3.70 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Assembly Biosciences Inc:

  • The EOD is 3.525. Based on the equity, the company is fair priced.
  • The MRQ is 3.701. Based on the equity, the company is fair priced.
  • The TTM is 2.234. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD3.525MRQ3.701-0.176
MRQ3.701TTM2.234+1.467
TTM2.234YOY0.111+2.123
TTM2.2345Y1.277+0.957
5Y1.27710Y2.612-1.335
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD3.5251.933+1.592
MRQ3.7012.265+1.436
TTM2.2342.447-0.213
YOY0.1112.454-2.343
5Y1.2773.664-2.387
10Y2.6124.239-1.627
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Assembly Biosciences Inc.

4.8.1. Institutions holding Assembly Biosciences Inc

Institutions are holding 18.792% of the shares of Assembly Biosciences Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-09-30Armistice Capital, LLC5.56930.0857354000-114000-24.359
2024-09-30Vanguard Group Inc3.15370.000120045800
2024-09-30BlackRock Inc1.2131077108-125-0.1618
2024-09-30Renaissance Technologies Corp1.03240.0015656241071319.5098
2024-09-30Acuitas Investments, LLC0.98040.4207623151231924.64
2024-09-30Geode Capital Management, LLC0.740.000147034-7375-13.5547
2024-09-30Millennium Management LLC0.59080.000337553-85905-69.5824
2024-09-30Northern Trust Corp0.46920.00012982418257157.8369
2024-09-30Federated Hermes Inc0.39950.00082539400
2024-09-30Susquehanna International Group, LLP0.2495015857-1543-8.8678
2024-09-30FMR Inc0.2494015855363529.7463
2024-09-30Bridgeway Capital Management, LLC0.22810.00481450000
2024-09-30State Street Corp0.201501280900
2024-09-30Marshall Wace Asset Management Ltd0.20020.000212725127250
2024-09-30Citadel Advisors Llc0.2001012720-26-0.204
2024-09-30Marquette Asset Management Inc.0.14180.0216901600
2024-09-30Amundi0.12480793400
2024-09-30JPMorgan Chase & Co0.05520350934425137.3134
2024-09-30Barclays PLC0.047703035411.3694
2024-09-30Morgan Stanley - Brokerage Accounts0.041802660-2464-48.0874
Total 15.88850.53591009930-150306-14.9%

4.9.2. Funds holding Assembly Biosciences Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-11-30Vanguard Total Stock Mkt Idx Inv1.80580.000111478200
2024-11-30Vanguard Institutional Extnd Mkt Idx Tr1.04390.00096635600
2024-09-30Federated Hermes MDT SCG Institutional0.39950.07612539400
2024-09-30Federated Hermes MDT Small Cap Growth IS0.39950.07612539400
2024-11-30Fidelity Extended Market Index0.36980.000923505-155-0.6551
2024-09-30Vanguard Strategic Small-Cap Equity Inv0.27880.01511772300
2024-09-30Bridgeway Ultra-Small Company Market0.21630.11891375000
2024-12-31Fidelity Enhanced Small Cap ETF0.21320.01831355300
2024-11-30Fidelity Total Market Index0.1350.0001858100
2024-12-31iShares Micro-Cap ETF0.12630.0133803100
2024-11-30SG Actions US Techno C0.12480.0314793400
2024-09-30Northern Small Cap Core I0.09750.0223620062000
2024-11-30Fidelity Series Total Market Index0.08820.00015608-28-0.4968
2024-09-30NT Ext Equity Mkt Idx Fd - NL0.08090.0011514400
2024-09-30Northern Trust Extended Eq Market Idx0.07930.001504100
2024-09-30NT Ext Equity Mkt Idx Fd - L0.07930.001504100
2024-12-31Extended Equity Market Fund K0.07790.00054954-68-1.354
2024-12-31Avantis US Small Cap Value ETF0.06920.0005439700
2024-09-30NT Ext Equity Mkt Idx Fd - DC - NL - T20.06520.00114145130.3146
2024-10-31Fidelity VIP Disciplined Small Cap Init0.06310.0151401300
Total 5.81350.3939369546+5962+1.6%

5.3. Insider Transactions

Insiders are holding 31.618% of the shares of Assembly Biosciences Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-12-30Michael HoughtonBUY320215.61
2024-11-18Nicole S WhiteSELL4016.29
2024-10-08Alexander SchornsteinBUY1000014.58
2024-10-03Jason A OkazakiSELL19714.81
2024-10-03Nicole S WhiteSELL15714.81
2024-07-05Alexander SchornsteinBUY443812.52
2024-07-03Alexander SchornsteinBUY456212.29
2024-05-23Jeanette M BjorkquistSELL2414.93
2024-05-23John G MchutchisonSELL211714.93
2024-05-23Jason A OkazakiSELL54914.93
2024-04-30Jason A OkazakiSELL156912.71
2024-04-30Nicole S WhiteSELL125512.71
2024-04-01Jason A OkazakiSELL35413.07
2024-04-01Jeanette M BjorkquistSELL11413.07
2024-04-01John G MchutchisonSELL120613.07
2024-03-27Jason A OkazakiSELL39212.87
2024-01-17Alexander SchornsteinBUY249999.36
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2024-09-30. Currency in USD. All numbers in thousands.

Summary
Total Assets100,262
Total Liabilities74,259
Total Stockholder Equity26,003
 As reported
Total Liabilities 74,259
Total Stockholder Equity+ 26,003
Total Assets = 100,262

Assets

Total Assets100,262
Total Current Assets98,213
Long-term Assets2,049
Total Current Assets
Cash And Cash Equivalents 28,452
Short-term Investments 66,502
Other Current Assets 3,259
Total Current Assets  (as reported)98,213
Total Current Assets  (calculated)98,213
+/-0
Long-term Assets
Property Plant Equipment 1,737
Long-term Assets Other 312
Long-term Assets  (as reported)2,049
Long-term Assets  (calculated)2,049
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities41,635
Long-term Liabilities32,624
Total Stockholder Equity26,003
Total Current Liabilities
Short-term Debt 1,329
Accounts payable 1,335
Other Current Liabilities 6,351
Total Current Liabilities  (as reported)41,635
Total Current Liabilities  (calculated)9,015
+/- 32,620
Long-term Liabilities
Capital Lease Obligations 1,442
Long-term Liabilities  (as reported)32,624
Long-term Liabilities  (calculated)1,442
+/- 31,182
Total Stockholder Equity
Common Stock6
Retained Earnings -815,590
Accumulated Other Comprehensive Income -156
Other Stockholders Equity 841,743
Total Stockholder Equity (as reported)26,003
Total Stockholder Equity (calculated)26,003
+/-0
Other
Capital Stock6
Cash and Short Term Investments 94,954
Common Stock Shares Outstanding 6,351
Current Deferred Revenue32,620
Liabilities and Stockholders Equity 100,262
Net Debt -27,010
Net Invested Capital 26,003
Net Working Capital 56,578
Property Plant and Equipment Gross 1,737
Short Long Term Debt Total 1,442



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-31
> Total Assets 
870
0
0
0
166
1,425
1,156
579
14,617
14,617
11,524
53,388
37,046
31,390
29,010
23,679
20,556
37,103
33,677
32,365
27,132
23,904
21,755
60,394
71,225
138,347
144,707
139,654
133,744
124,454
117,206
109,127
98,119
134,284
122,775
112,313
169,303
156,021
142,418
282,977
268,045
259,247
241,511
223,345
339,907
313,310
294,801
306,306
283,254
278,903
262,136
248,973
191,060
162,730
143,447
121,516
101,794
83,116
66,577
51,629
137,469
119,883
115,323
100,262
100,262115,323119,883137,46951,62966,57783,116101,794121,516143,447162,730191,060248,973262,136278,903283,254306,306294,801313,310339,907223,345241,511259,247268,045282,977142,418156,021169,303112,313122,775134,28498,119109,127117,206124,454133,744139,654144,707138,34771,22560,39421,75523,90427,13232,36533,67737,10320,55623,67929,01031,39037,04653,38811,52414,61714,6175791,1561,425166000870
   > Total Current Assets 
0
0
0
0
84
1,069
655
275
14,590
14,590
11,466
53,379
37,038
31,383
29,001
23,671
20,549
37,097
33,667
32,358
27,125
23,896
21,748
18,080
29,216
96,338
71,333
66,503
68,368
59,089
64,103
59,255
53,575
92,222
77,669
68,652
123,119
113,226
97,529
239,873
222,502
200,806
183,460
165,322
282,780
256,752
235,088
246,387
224,493
221,634
205,558
188,219
154,204
130,777
124,294
115,078
96,967
79,744
64,081
49,672
133,787
117,168
112,931
98,213
98,213112,931117,168133,78749,67264,08179,74496,967115,078124,294130,777154,204188,219205,558221,634224,493246,387235,088256,752282,780165,322183,460200,806222,502239,87397,529113,226123,11968,65277,66992,22253,57559,25564,10359,08968,36866,50371,33396,33829,21618,08021,74823,89627,12532,35833,66737,09720,54923,67129,00131,38337,03853,37911,46614,59014,5902756551,069840000
       Cash And Cash Equivalents 
16
0
0
0
81
1,068
650
271
14,571
14,571
11,369
53,294
36,975
31,067
28,844
23,560
20,489
36,874
33,490
32,223
27,061
23,637
21,316
17,933
29,091
96,054
53,518
36,401
27,108
20,395
20,341
23,794
28,575
70,818
39,453
27,247
82,033
66,927
54,192
119,752
41,471
29,107
34,258
24,867
46,732
42,326
96,709
58,311
59,444
78,253
59,517
70,760
45,627
51,174
43,063
54,673
52,418
43,482
21,623
26,656
19,841
18,749
19,208
28,452
28,45219,20818,74919,84126,65621,62343,48252,41854,67343,06351,17445,62770,76059,51778,25359,44458,31196,70942,32646,73224,86734,25829,10741,471119,75254,19266,92782,03327,24739,45370,81828,57523,79420,34120,39527,10836,40153,51896,05429,09117,93321,31623,63727,06132,22333,49036,87420,48923,56028,84431,06736,97553,29411,36914,57114,5712716501,0688100016
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
17,209
29,396
40,557
37,928
43,205
34,851
24,388
20,105
36,124
39,053
37,914
42,232
38,480
114,188
176,609
164,429
139,553
132,070
227,311
206,803
130,005
179,630
156,969
136,631
139,560
110,142
101,000
71,826
73,626
53,978
39,192
29,534
38,208
19,554
110,406
94,227
90,011
66,502
66,50290,01194,227110,40619,55438,20829,53439,19253,97873,62671,826101,000110,142139,560136,631156,969179,630130,005206,803227,311132,070139,553164,429176,609114,18838,48042,23237,91439,05336,12420,10524,38834,85143,20537,92840,55729,39617,20900000000000000000000000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
260
0
0
0
0
0
0
0
0
0
0
0
1,114
1,400
2,273
2,264
2,126
2,590
2,430
2,987
2,903
2,944
3,374
3,055
3,315
3,590
1,230
203
297
769
336
524
523
1,246
944
717
342
100
43
43
400
0
040043431003427179441,2465235243367692972031,2303,5903,3153,0553,3742,9442,9032,9872,4302,5902,1262,2642,2731,4001,114000000000002600000000000000000000000
       Inventory 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-100
0
0
0
0
0000-10000000000000000000000000000000000000000000000000000000000000
   > Long-term Assets 
0
0
0
0
82
356
501
304
27
27
58
9
8
7
9
8
7
6
9
8
7
8
7
42,314
42,009
42,009
73,374
73,151
65,376
65,365
53,103
49,872
44,544
42,063
45,106
43,661
46,185
42,795
44,889
43,104
45,543
58,441
58,051
58,023
57,127
56,558
59,713
59,919
58,761
57,269
56,578
60,754
36,856
31,953
19,153
6,438
4,827
3,372
2,496
1,957
3,682
2,715
2,392
2,049
2,0492,3922,7153,6821,9572,4963,3724,8276,43819,15331,95336,85660,75456,57857,26958,76159,91959,71356,55857,12758,02358,05158,44145,54343,10444,88942,79546,18543,66145,10642,06344,54449,87253,10365,36565,37673,15173,37442,00942,00942,314787896789789582727304501356820000
       Property Plant Equipment 
17
0
0
0
13
11
10
9
0
11
10
9
8
7
9
8
7
6
9
8
7
8
7
34
156
173
174
156
149
132
114
128
215
183
132
593
860
732
640
516
557
15,142
14,720
14,714
13,805
13,259
12,843
12,301
10,731
9,597
8,847
8,014
7,181
6,319
5,610
4,825
3,938
3,038
2,164
1,405
2,724
2,403
2,080
1,737
1,7372,0802,4032,7241,4052,1643,0383,9384,8255,6106,3197,1818,0148,8479,59710,73112,30112,84313,25913,80514,71414,72015,1425575166407328605931321832151281141321491561741731563478789678978910110910111300017
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
12,143
12,737
12,737
12,638
12,638
12,638
12,638
12,638
12,638
12,638
12,638
12,638
12,638
12,638
12,638
12,638
12,638
12,638
12,638
12,638
12,638
12,638
12,638
12,638
12,638
12,638
12,638
12,638
12,638
0
0
0
0
0
0
0
0
0
0
0
0
00000000000012,63812,63812,63812,63812,63812,63812,63812,63812,63812,63812,63812,63812,63812,63812,63812,63812,63812,63812,63812,63812,63812,63812,63812,63812,63812,63812,73712,73712,14300000000000000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
31,437
31,186
23,392
23,390
11,167
7,900
2,436
0
0
0
3,347
0
2,204
0
0
0
0
0
0
0
0
0
0
0
0
9,180
27,972
23,459
11,908
0
0
0
0
0
0
0
0
0
00000000011,90823,45927,9729,1800000000000002,20403,3470002,4367,90011,16723,39023,39231,18631,43700000000000000000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
30,137
29,000
29,000
29,000
29,000
29,000
29,000
29,000
29,000
29,000
29,000
29,000
29,000
29,000
29,000
29,000
29,000
29,000
29,000
29,000
29,000
29,000
29,000
29,000
29,000
29,000
29,000
29,000
29,000
0
0
0
0
0
0
0
0
0
0
0
0
00000000000029,00029,00029,00029,00029,00029,00029,00029,00029,00029,00029,00029,00029,00029,00029,00029,00029,00029,00029,00029,00029,00029,00029,00029,00029,00029,00029,00029,00030,13700000000000000000000000
       Long-term Assets Other 
0
0
0
0
70
345
491
295
27
27
48
0
0
0
0
0
0
0
0
0
0
0
0
0
115
99
125
170
197
204
184
205
255
242
327
426
340
426
407
951
3,348
1,661
1,693
1,671
1,684
1,661
5,232
5,980
6,392
6,034
6,093
1,922
1,703
2,175
1,635
1,613
78
334
332
552
312
312
312
312
312312312312552332334781,6131,6352,1751,7031,9226,0936,0346,3925,9805,2321,6611,6841,6711,6931,6613,348951407426340426327242255205184204197170125991150000000000000482727295491345700000
> Total Liabilities 
10,327
0
0
0
13,529
14,924
16,224
17,536
2,990
2,990
2,090
1,183
2,513
3,853
3,392
2,681
2,745
1,977
2,585
2,318
2,638
1,462
1,470
13,192
12,654
13,728
13,840
14,252
15,003
15,169
16,645
19,082
18,241
66,396
66,240
65,180
56,184
53,640
53,318
53,544
57,392
68,846
66,804
66,856
66,690
61,542
27,686
35,757
42,676
31,659
30,342
24,328
22,131
15,939
19,467
19,112
19,130
12,783
11,628
9,915
96,372
87,282
80,641
74,259
74,25980,64187,28296,3729,91511,62812,78319,13019,11219,46715,93922,13124,32830,34231,65942,67635,75727,68661,54266,69066,85666,80468,84657,39253,54453,31853,64056,18465,18066,24066,39618,24119,08216,64515,16915,00314,25213,84013,72812,65413,1921,4701,4622,6382,3182,5851,9772,7452,6813,3923,8532,5131,1832,0902,9902,99017,53616,22414,92413,52900010,327
   > Total Current Liabilities 
4,712
0
0
0
12,357
13,729
15,000
16,290
1,720
1,720
770
1,183
2,513
3,853
3,392
2,681
2,745
1,977
2,585
2,318
2,638
1,462
1,470
1,049
1,054
2,128
2,240
2,652
3,403
3,569
5,045
7,482
7,121
10,957
11,989
12,219
13,492
12,180
13,131
14,610
18,472
25,205
19,935
21,498
24,440
21,146
17,271
16,804
24,433
14,497
13,910
14,928
16,073
10,709
14,961
15,461
16,296
9,970
8,831
7,132
39,225
38,753
41,274
41,635
41,63541,27438,75339,2257,1328,8319,97016,29615,46114,96110,70916,07314,92813,91014,49724,43316,80417,27121,14624,44021,49819,93525,20518,47214,61013,13112,18013,49212,21911,98910,9577,1217,4825,0453,5693,4032,6522,2402,1281,0541,0491,4701,4622,6382,3182,5851,9772,7452,6813,3923,8532,5131,1837701,7201,72016,29015,00013,72912,3570004,712
       Short-term Debt 
0
0
0
0
7,841
10,199
10,688
7,426
1,219
1,219
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,704
2,854
3,208
3,186
3,264
3,250
3,338
3,404
2,934
3,048
3,099
3,151
3,207
3,311
3,371
3,364
2,546
1,702
869
1,220
2,290
2,590
1,329
1,3292,5902,2901,2208691,7022,5463,3643,3713,3113,2073,1513,0993,0482,9343,4043,3383,2503,2643,1863,2082,8542,70400000000000000000000000000000001,2191,2197,42610,68810,1997,8410000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,704
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000002,70400000000000000000000000000000000000000000
       Accounts payable 
4,125
0
0
0
3,362
2,136
1,676
1,282
313
313
622
1,183
2,342
3,143
3,158
1,843
1,847
1,527
2,132
2,280
2,615
1,435
1,421
1,049
908
1,251
1,304
1,464
1,364
2,326
2,414
3,838
2,368
1,947
688
871
2,124
2,373
2,539
2,988
3,693
2,427
3,414
2,709
1,731
2,104
3,640
1,611
4,598
3,562
2,866
2,628
2,659
1,407
2,454
1,942
2,493
1,224
904
758
461
727
801
1,335
1,3358017274617589041,2242,4931,9422,4541,4072,6592,6282,8663,5624,5981,6113,6402,1041,7312,7093,4142,4273,6932,9882,5392,3732,1248716881,9472,3683,8382,4142,3261,3641,4641,3041,2519081,0491,4211,4352,6152,2802,1321,5271,8471,8433,1583,1432,3421,1836223133131,2821,6762,1363,3620004,125
       Other Current Liabilities 
417
0
0
0
1,154
1,394
2,636
5,617
188
188
148
0
171
710
234
838
898
449
454
37
23
27
48
1,049
146
878
936
1,187
2,039
1,243
2,631
3,644
4,753
4,014
6,306
6,353
6,139
4,647
5,080
6,517
9,679
10,141
7,585
9,430
13,112
9,063
10,381
2,868
7,444
-986
-991
6,468
7,530
3,362
6,463
7,415
7,706
3,467
3,492
2,772
6,629
2,965
4,823
6,351
6,3514,8232,9656,6292,7723,4923,4677,7067,4156,4633,3627,5306,468-991-9867,4442,86810,3819,06313,1129,4307,58510,1419,6796,5175,0804,6476,1396,3536,3064,0144,7533,6442,6311,2432,0391,1879368781461,0494827233745444989883823471017101481881885,6172,6361,3941,154000417
   > Long-term Liabilities 
0
0
0
0
1,171
1,195
1,224
1,246
1,271
1,271
1,320
0
0
0
0
0
898,213
0
0
0
23,435
0
0
12,143
11,600
11,600
11,600
11,600
11,600
11,600
11,600
11,600
11,120
55,439
54,250
52,961
42,692
41,460
40,187
38,934
38,920
43,641
46,869
45,358
42,250
40,396
10,415
18,953
18,243
17,162
16,432
9,400
6,058
5,230
4,506
3,651
2,834
2,813
2,797
2,783
57,147
48,529
39,367
32,624
32,62439,36748,52957,1472,7832,7972,8132,8343,6514,5065,2306,0589,40016,43217,16218,24318,95310,41540,39642,25045,35846,86943,64138,92038,93440,18741,46042,69252,96154,25055,43911,12011,60011,60011,60011,60011,60011,60011,60011,60012,1430023,435000898,213000001,3201,2711,2711,2461,2241,1951,1710000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
11,600
0
0
0
11,600
0
0
0
11,120
44,319
43,075
41,815
40,555
41,460
40,187
38,934
38,920
33,120
36,834
35,519
33,168
31,857
2,531
11,518
11,518
11,518
11,518
5,264
2,733
2,733
2,733
2,733
0
0
2,733
0
0
0
0
0
000002,733002,7332,7332,7332,7335,26411,51811,51811,51811,5182,53131,85733,16835,51936,83433,12038,92038,93440,18741,46040,55541,81543,07544,31911,12000011,60000011,600000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
11,600
11,600
11,600
0
55,439
54,250
52,961
0
41,460
40,187
38,934
38,920
0
36,834
3,251
2,531
2,531
2,531
2,531
2,531
2,531
800
2,531
200
200
200
200
0
0
200
0
0
0
0
0
00000200002002002002002,5318002,5312,5312,5312,5312,5312,5313,25136,834038,92038,93440,18741,460052,96154,25055,439011,60011,60011,60000000000000000000000000000000
> Total Stockholder Equity
0
0
0
0
-13,363
-13,499
-15,068
-16,957
11,626
11,626
9,434
52,205
34,533
27,537
25,619
20,998
17,810
35,126
31,091
30,048
24,494
22,442
20,285
47,202
58,571
124,619
130,867
125,402
118,742
109,285
100,561
90,045
79,878
67,888
56,535
47,133
113,120
102,381
89,101
229,433
210,653
190,401
174,707
156,489
273,217
251,768
267,115
270,549
240,578
247,244
231,794
224,645
168,929
146,791
123,980
102,404
82,664
70,333
54,949
41,714
41,097
32,601
34,682
26,003
26,00334,68232,60141,09741,71454,94970,33382,664102,404123,980146,791168,929224,645231,794247,244240,578270,549267,115251,768273,217156,489174,707190,401210,653229,43389,101102,381113,12047,13356,53567,88879,87890,045100,561109,285118,742125,402130,867124,61958,57147,20220,28522,44224,49430,04831,09135,12617,81020,99825,61927,53734,53352,2059,43411,62611,626-16,957-15,068-13,499-13,3630000
   Common Stock
0
0
0
0
0
6
6
0
7
7
7
12
12
12
13
13
13
20
20
21
21
23
5
9
11
16
17
17
17
17
17
17
17
17
17
17
20
20
21
25
25
26
26
26
32
32
33
33
34
40
44
47
48
48
48
48
49
52
52
53
5
5
6
6
665553525249484848484744403433333232262626252521202017171717171717171717161195232121202013131312121277706600000
   Retained Earnings Total Equity000000-743,470-724,520-702,125-678,980-654,5190-571,171-552,368-528,773-501,573-462,155-458,806-466,076-439,421-412,337-387,342-368,839-341,787-315,626-294,091-267,285-251,036-248,029-235,757-222,158-208,227-196,681-185,107-174,954-163,966-156,218-149,600-142,657-135,512-129,283-118,262-115,793-111,723-105,676-100,794-96,043-92,320-88,528-83,173-75,703-67,529-48,670-42,8680000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
-15
0
0
0
-27
-27
0
0
-28
-28
0
0
-33
0
369
369
-39
369
369
369
0
-64
-134
-388
-822
-749
-839
-837
-601
-525
-398
-388
-392
-459
-372
-355
-347
-239
-187
-205
-201
-86
104
-158
-270
-271
-273
-288
-419
-908
-998
-999
-803
-513
-325
-275
-81
-239
-293
-156
-156-293-239-81-275-325-513-803-999-998-908-419-288-273-271-270-158104-86-201-205-187-239-347-355-372-459-392-388-398-525-601-837-839-749-822-388-134-640369369369-393693690-3300-28-2800-27-27000-150000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
52,295
100,862
102,049
103,228
108,779
109,514
110,117
131,149
131,497
135,334
135,828
137,843
138,174
176,108
194,073
267,260
280,584
281,991
283,512
284,972
286,490
287,545
288,689
290,554
292,673
295,533
364,528
370,105
383,543
545,389
552,762
559,453
562,210
569,005
712,807
717,898
725,784
732,829
742,387
776,248
784,391
796,057
0
802,170
803,910
805,480
807,938
814,264
0
0
0
0
0
0
000000814,264807,938805,480803,910802,1700796,057784,391776,248742,387732,829725,784717,898712,807569,005562,210559,453552,762545,389383,543370,105364,528295,533292,673290,554288,689287,545286,490284,972283,512281,991280,584267,260194,073176,108138,174137,843135,828135,334131,497131,149110,117109,514108,779103,228102,049100,86252,2950000000000
   Treasury Stock0000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
4,545
6,410
6,969
6,861
44,831
44,831
52,295
100,862
102,078
103,228
108,779
109,514
110,150
131,149
131,497
135,334
136,236
137,843
138,174
176,108
194,073
267,324
280,584
281,991
283,512
284,972
286,490
287,545
288,689
290,554
292,673
295,533
364,528
370,105
383,543
545,389
552,762
559,453
562,210
569,005
712,807
717,898
725,784
732,829
742,387
776,248
784,391
796,057
800,728
802,170
803,910
805,480
807,938
814,264
815,588
816,722
826,921
827,660
840,946
841,743
841,743840,946827,660826,921816,722815,588814,264807,938805,480803,910802,170800,728796,057784,391776,248742,387732,829725,784717,898712,807569,005562,210559,453552,762545,389383,543370,105364,528295,533292,673290,554288,689287,545286,490284,972283,512281,991280,584267,324194,073176,108138,174137,843136,236135,334131,497131,149110,150109,514108,779103,228102,078100,86252,29544,83144,8316,8616,9696,4104,5450000



5.3. Balance Sheets

Currency in USD. All numbers in thousands.